Infliximab Pricing in International Economic Evaluations in Inflammatory Bowel Disease to Inform Biologic and Biosimilar Access Policies: A Systematic Review

Background. Policies mandating the use of lower cost biosimilars in patients with inflammatory bowel disease (IBD) have created concerns for patients who prefer their original biologic. Purpose. To inform the cost-effectiveness of biosimilar infliximab treatment in IBD by systematically reviewing th...

Descripción completa

Detalles Bibliográficos
Autores principales: Bashir, Naazish S., Hughes, Avery, Ungar, Wendy J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969457/
https://www.ncbi.nlm.nih.gov/pubmed/36860664
http://dx.doi.org/10.1177/23814683231156433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969457/
https://www.ncbi.nlm.nih.gov/pubmed/36860664
http://dx.doi.org/10.1177/23814683231156433

Ejemplares similares